News and ViewsIs Halozyme Therapeutics, Inc. technically bullish or bearish?
2025-11-05 11:22:04As of 31 October 2025, the technical trend for Halozyme Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish. The daily moving averages are mildly bullish, and Bollinger Bands show bullish signals for both weekly and monthly time frames. However, the KST and Dow Theory indicate no clear trend on both weekly and monthly levels. In terms of performance, the stock has outperformed the S&P 500 over the past week with a return of 3.34% compared to 0.71%, but it has underperformed over the past month with a return of -1.35% against the S&P 500's 1.92%. Year-to-date, the stock has a strong return of 42.33% versus the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and Bollinger Bands....
Read MoreIs Halozyme Therapeutics, Inc. technically bullish or bearish?
2025-11-04 11:33:28As of 31 October 2025, the technical trend for Halozyme Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting a positive short-term outlook. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. KST and Dow Theory are both bullish on both weekly and monthly time frames, which adds to the overall positive sentiment. However, the weekly OBV is mildly bearish, suggesting some selling pressure. Overall, the current stance is mildly bullish, but with some caution due to mixed indicators. Multi-period return data is not available for comparison with the S&P 500....
Read MoreIs Halozyme Therapeutics, Inc. technically bullish or bearish?
2025-11-03 11:33:14As of 31 October 2025, the technical trend for Halozyme Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish. The daily moving averages indicate a mildly bullish stance. The KST and Dow Theory are both bullish on a weekly and monthly basis, suggesting underlying strength. However, the weekly OBV is mildly bearish, which could indicate some selling pressure. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.45% and -13.01% compared to the S&P 500's gains of 0.71% and 1.92%, respectively. However, year-to-date and one-year returns are strong at 36.35% and 28.91%, respectively, outperforming the S&P 500's 16.30% and 19.89%. Overall, the current stance is mildly bullish, with mixed signals across different indicators....
Read MoreIs Halozyme Therapeutics, Inc. technically bullish or bearish?
2025-11-02 11:17:57As of 31 October 2025, the technical trend for Halozyme Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed momentum. The daily moving averages are mildly bullish, suggesting some short-term strength. The Bollinger Bands show a sideways trend on the weekly chart but are mildly bullish on the monthly chart. KST and Dow Theory are both bullish across weekly and monthly time frames, reinforcing a generally positive outlook. However, the weekly OBV is mildly bearish, which could indicate some selling pressure. Overall, the technical stance is mildly bullish, with key indicators such as the monthly MACD and KST supporting this view. Unfortunately, multi-period return data is not available for comparison with the S&P 500....
Read MoreIs Halozyme Therapeutics, Inc. overvalued or undervalued?
2025-10-21 12:08:17As of 17 October 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 10.96, and a PEG ratio of 0.22, which suggests strong growth potential relative to its price. In comparison to peers, Halozyme's P/E ratio of 14 is lower than Illumina, Inc. at 19.09 and BioMarin Pharmaceutical, Inc. at 15.17, indicating it may be a more attractive investment relative to these companies. Additionally, the company's ROE of 100.64% is significantly higher than the industry average, highlighting its efficiency in generating profits. Over the past year, Halozyme has returned 28.21%, outperforming the S&P 500's return of 14.08%, reinforcing its competitive position in the market....
Read More
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
2025-10-20 16:11:24Halozyme Therapeutics, Inc. has recently adjusted its valuation, with its stock price at $67.03. Over the past year, it has achieved a 28.21% return, surpassing the S&P 500. The company exhibits strong financial metrics, including a P/E ratio of 14 and a remarkable return on equity of 100.64%.
Read MoreIs Halozyme Therapeutics, Inc. overvalued or undervalued?
2025-10-20 12:25:43As of 17 October 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 10.96, and a PEG ratio of 0.22, which suggests strong growth potential relative to its price. In comparison to peers, Halozyme's P/E ratio is lower than Illumina, Inc. at 19.09 and BioMarin Pharmaceutical, Inc. at 15.17, indicating it may be more attractively priced within its industry. Notably, Halozyme has a high ROE of 100.64% and ROCE of 48.11%, showcasing its efficient use of capital. Over the past year, Halozyme has returned 28.21%, outperforming the S&P 500's return of 14.08%, reinforcing its favorable valuation narrative....
Read MoreIs Halozyme Therapeutics, Inc. overvalued or undervalued?
2025-10-19 12:03:17As of 17 October 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. The P/E ratio stands at 14, the EV to EBITDA ratio is 10.96, and the PEG ratio is notably low at 0.22, indicating strong growth potential relative to its price. In comparison to its peers, Halozyme's P/E ratio is lower than Illumina, Inc. at 19.09 and BioMarin Pharmaceutical, Inc. at 15.17, suggesting it is competitively priced within the industry. The company's strong ROE of 100.64% and ROCE of 48.11% further support its valuation. Over the past year, Halozyme has returned 28.21%, outperforming the S&P 500's return of 14.08%, reinforcing its position as a solid investment....
Read More
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals
2025-10-07 19:46:08Halozyme Therapeutics, Inc. has recently revised its market evaluation, with its stock priced at $66.97. The company has shown varied performance compared to the S&P 500, achieving a 13.16% return over the past year and a notable 152.72% return over five years, despite trailing the index's longer-term growth.
Read More
Announcement
Corporate ActionsCorporate Actions
